Cargando…

Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study

OBJECTIVES: To develop a register-based monitoring system to provide information on the use of lipid-lowering medication among persons with diabetes in different patient groups and by socioeconomic position. DESIGN: Longitudinal and register-based, before and after diabetes diagnosis. SETTING: Finni...

Descripción completa

Detalles Bibliográficos
Autores principales: Vehko, Tuulikki, Sund, Reijo, Arffman, Martti, Manderbacka, Kristiina, Ilanne-Parikka, Pirjo, Keskimäki, Ilmo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822306/
https://www.ncbi.nlm.nih.gov/pubmed/24189078
http://dx.doi.org/10.1136/bmjopen-2013-003414
_version_ 1782290394959052800
author Vehko, Tuulikki
Sund, Reijo
Arffman, Martti
Manderbacka, Kristiina
Ilanne-Parikka, Pirjo
Keskimäki, Ilmo
author_facet Vehko, Tuulikki
Sund, Reijo
Arffman, Martti
Manderbacka, Kristiina
Ilanne-Parikka, Pirjo
Keskimäki, Ilmo
author_sort Vehko, Tuulikki
collection PubMed
description OBJECTIVES: To develop a register-based monitoring system to provide information on the use of lipid-lowering medication among persons with diabetes in different patient groups and by socioeconomic position. DESIGN: Longitudinal and register-based, before and after diabetes diagnosis. SETTING: Finnish population. PARTICIPANTS: A total of 121 053 persons aged 30–79 years with a new diagnosis of diabetes during 2000–2006. The annual cohorts were divided at the time of diabetes diagnosis by coronary heart disease (CHD) status. PRIMARY AND SECONDARY OUTCOME MEASURES: Lipid-lowering medication purchases after diabetes diagnosis and prior to the diagnosis. RESULTS: According to the health insurance reimbursement data the use of lipid-lowering medication advanced rapidly among people with diabetes in the early 2000s in Finland. Of the patients diagnosed with diabetes in 2000 only one-fourth used lipid-lowering medication in 6–12 months after their diagnosis. For those diagnosed in 2006, the utilization rate was 46%. Among those with a history of CHD the use of medication was markedly higher; 51–58% in 2000 and 77–79% in 2006. Taking into account the increasing trend and measuring the independent effect of the diagnosis of diabetes on lipid-lowering medication, setting the diagnosis increased the use by 10–50%. Despite increasing overall utilisation rates, socioeconomic difference in the use of lipid-lowering medication remained throughout the study period. In particular, the lowest income quintile differed from other income groups and in 2006 its use of lipid-lowering medication remained approximately 10% points lower compared with the overall level. CONCLUSIONS: The lipid-lowering medication is being applied in an increasing population of new diabetes cases; however, modelling the independent effect of the diagnosis of diabetes on lipid-lowering medication shows that the diagnosis increased use, but did not abolish socioeconomic differences.
format Online
Article
Text
id pubmed-3822306
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38223062013-11-12 Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study Vehko, Tuulikki Sund, Reijo Arffman, Martti Manderbacka, Kristiina Ilanne-Parikka, Pirjo Keskimäki, Ilmo BMJ Open Health Services Research OBJECTIVES: To develop a register-based monitoring system to provide information on the use of lipid-lowering medication among persons with diabetes in different patient groups and by socioeconomic position. DESIGN: Longitudinal and register-based, before and after diabetes diagnosis. SETTING: Finnish population. PARTICIPANTS: A total of 121 053 persons aged 30–79 years with a new diagnosis of diabetes during 2000–2006. The annual cohorts were divided at the time of diabetes diagnosis by coronary heart disease (CHD) status. PRIMARY AND SECONDARY OUTCOME MEASURES: Lipid-lowering medication purchases after diabetes diagnosis and prior to the diagnosis. RESULTS: According to the health insurance reimbursement data the use of lipid-lowering medication advanced rapidly among people with diabetes in the early 2000s in Finland. Of the patients diagnosed with diabetes in 2000 only one-fourth used lipid-lowering medication in 6–12 months after their diagnosis. For those diagnosed in 2006, the utilization rate was 46%. Among those with a history of CHD the use of medication was markedly higher; 51–58% in 2000 and 77–79% in 2006. Taking into account the increasing trend and measuring the independent effect of the diagnosis of diabetes on lipid-lowering medication, setting the diagnosis increased the use by 10–50%. Despite increasing overall utilisation rates, socioeconomic difference in the use of lipid-lowering medication remained throughout the study period. In particular, the lowest income quintile differed from other income groups and in 2006 its use of lipid-lowering medication remained approximately 10% points lower compared with the overall level. CONCLUSIONS: The lipid-lowering medication is being applied in an increasing population of new diabetes cases; however, modelling the independent effect of the diagnosis of diabetes on lipid-lowering medication shows that the diagnosis increased use, but did not abolish socioeconomic differences. BMJ Publishing Group 2013-11-04 /pmc/articles/PMC3822306/ /pubmed/24189078 http://dx.doi.org/10.1136/bmjopen-2013-003414 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Health Services Research
Vehko, Tuulikki
Sund, Reijo
Arffman, Martti
Manderbacka, Kristiina
Ilanne-Parikka, Pirjo
Keskimäki, Ilmo
Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study
title Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study
title_full Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study
title_fullStr Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study
title_full_unstemmed Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study
title_short Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study
title_sort monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study
topic Health Services Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822306/
https://www.ncbi.nlm.nih.gov/pubmed/24189078
http://dx.doi.org/10.1136/bmjopen-2013-003414
work_keys_str_mv AT vehkotuulikki monitoringtheuseoflipidloweringmedicationamongpersonswithnewlydiagnoseddiabetesanationwideregisterbasedstudy
AT sundreijo monitoringtheuseoflipidloweringmedicationamongpersonswithnewlydiagnoseddiabetesanationwideregisterbasedstudy
AT arffmanmartti monitoringtheuseoflipidloweringmedicationamongpersonswithnewlydiagnoseddiabetesanationwideregisterbasedstudy
AT manderbackakristiina monitoringtheuseoflipidloweringmedicationamongpersonswithnewlydiagnoseddiabetesanationwideregisterbasedstudy
AT ilanneparikkapirjo monitoringtheuseoflipidloweringmedicationamongpersonswithnewlydiagnoseddiabetesanationwideregisterbasedstudy
AT keskimakiilmo monitoringtheuseoflipidloweringmedicationamongpersonswithnewlydiagnoseddiabetesanationwideregisterbasedstudy